. Author manuscript; available in PMC: 2017 Aug 25.

Published in final edited form as: Acad Radiol. 2016 Jul 18;23(9):1073–1082. doi: 10.1016/j.acra.2016.04.004

TABLE 2.

Comparison of Pre- and Post-therapeutic Diffusion-weighted Imaging for All Patients

	T2 Area	T2	T2	T2	CE Area	CE	CE	CE
	(cm²)	rADC_min	rADC_mean	rADC_max	(cm²)	rADC_min	rADC_mean	rADC_max
PreTx	13.4(12.2)	0.99 (0.15)	1.66 (0.34)	2.12 (0.40)	2.36 (2.94)	1.12 (0.33)	1.51 (0.23)	1.88 (0.43)
PostTx	17.7 (9.8)	0.71 (0.21)	1.30 (0.18)	2.02 (0.54)	3.82 (7.08)	0.82 (0.23)	1.20 (0.33)	1.61 (0.55)
P value	0.16	0.01	0.01	0.41	0.34	0.01	0.01	0.05

CE, contrast enhancing region of interest; Mean (standard deviation), T2, T2 FLAIR hyperintensity region of interest; PostTx, following bevacizumab administration; PreTx, before bevacizumab administration.